Canaccord lowered the firm’s price target on Nevro to $11 from $17 and keeps a Hold rating on the shares. The firm said the company has paused its PDN-Sensory study, as it believes it can achieve powered, guideline-altering results with its current enrollment, but did not provide timing for data release.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVRO: